Pharmafile Logo
Pharmafocus logo
Advanced Search

multiple myeloma

Showing 15 posts of 81 posts found.

NICE publishes new myeloma guidance

February 10, 2016
Medical Communications, Research and Development Farydak, Novartis, multiple myeloma

NICE has set out best practice for the diagnosis, monitoring and treatment of myeloma, in new guidelines published today. Myeloma …

News
Amgen image

FDA approves new Kyprolis combo for multiple myeloma

January 22, 2016
Medical Communications, Sales and Marketing Amgen, FDA, Kyprolis, carfilzomib, multiple myeloma, myeloma

Amgen’s Kyprolis has been given another endorsement by the FDA as a multiple myeloma treatment – its second in six …

News
Ninlaro

Takeda in myeloma research drive

January 14, 2016
Medical Communications, Research and Development Ninlaro, Phase II, Takeda, Takeda oncology, eric low, ixazomib, multiple myeloma, myeloma

Takeda is funding the research charity Myeloma UK to run a Phase II study of its multiple myeloma treatment Ninlaro, …

News
Scotland flag

Cancer and MS drugs approved in Scotland

December 9, 2015
Sales and Marketing Celgene, Copaxone, Novartis, SMC, Scottish Medicines Consortium, Tevaq, ceritinib, glatiramer acetate, lenalidomide, lung cancer, multiple myeloma, multiple sclerosis, revlimis, zykadia

The Scottish Medicines Consortium (SMC) has approved three new treatments for lung cancer, multiple sclerosis and multiple myeloma, from Novartis, …

News
Ninlaro

Takeda’s Ninlaro extends myeloma survival in trial

December 7, 2015
Manufacturing and Production, Research and Development Ninlaro, Takeda, ash, ixazomib, multiple myeloma

Takeda has presented trial data showing that treatment with its oral proteasome inhibitor Ninlaro extended progression free survival by 35% …

News
Keytruda image

MSD’s Keytruda shows promise in multiple myeloma

December 7, 2015
Manufacturing and Production MSD, Revlimid, dexamethasone, keytruda, multiple myeloma, pembrolizumab

MSD has announced that it has initiated two Phase III studies based in part on the strength of early data, …

News
kyprolis_amgen

Amgen’s Kyprolis doubles Velcade benefit in head-to-head study

December 5, 2015
Research and Development, Sales and Marketing Amgen, Cancer, Kyprolis, Takeda, Velcade, multiple myeloma

Amgen has announced that its multiple myeloma therapy Kyprolis displayed superiority to Takeda’s Velcade in the Phase III ENDEAVOR study …

News
Empliciti logo

FDA approves BMS and AbbVie’s Empliciti for multiple myeloma

December 1, 2015
Manufacturing and Production, Sales and Marketing AbbVie, BMS, Bristol-Myers Squibb, Empliciti, FDA, elotuzumab, multiple myeloma

The US healthcare regulator has approved Empliciti – a multiple myeloma treatment co-developed by Bristol-Myers Squibb and AbbVie. The FDA …

News
Clinigen logo

Clinigen launches UK managed access program for Takeda’s ixazomib

November 30, 2015
Sales and Marketing Clinigen, Takeda, ixazomib, managed access, multiple myeloma, oncology

Clinigen and Takeda have struck a deal to allow patients in the UK to access the multiple myeloma drug ixazomib …

News
Takeda oncology

Challenges in oncology R&D

November 18, 2015
Manufacturing and Production, Research and Development Dixie-Lee Esseltine, Takeda, Takeda oncology, Velcade, multiple myeloma, oncology

Pharmafile put questions on the challenges pharma companies face when working in oncology R&D to Dixie-Lee Esseltine, vice president of …

Feature
Amgen image

Amgen’s Kyprolis gets accelerated FDA review for expanded labelling

September 21, 2015
Sales and Marketing Amgen, FDA, Kyprolis, carfilzomib, multiple myeloma

The FDA has accepted for priority review Amgen’s supplemental new drug application for Kyprolis (carfilzomib) for patients with relapsed multiple …

News
Farydak

NICE rejects Farydak for multiple myeloma

September 16, 2015
Sales and Marketing Farydak, NICE, Novartis, multiple myeloma, panobinostat

NICE has rejected Novartis Farydak in its draft guidance, ruling it out as a treatment for multiple myeloma. Farydak (panobinostat) is …

News
janssen_stairs

Janssen submits EMA application for myeloma drug

September 14, 2015
Sales and Marketing Janssen, daratumumab, multiple myeloma

Janssen has submitted a new marketing authorisation application for European approval of daratumumab for the treatment of patients with relapsed …

News
Farydak

Novartis blood cancer drug Farydak receives EU approval

September 4, 2015
Sales and Marketing Cancer, European Commission, Farydak, Novartis, multiple myeloma, myeloma, panobinostat

The European Commission has approved Novartis’s Farydak, in combination with Velcade and dexamethasone, for the treatment of adult patients with …

News

Takeda gets European MAA approval for ixazomib

August 21, 2015
Medical Communications, Research and Development (FDA/EMA/MHRA), FDA/EMA/MHRA, Takeda, ixazomib, multiple myeloma

Takeda has announced that the European Medicines Agency (EMA) has accepted its Marketing Authorisation Application (MAA) for ixazomib, an investigational …

News
The Gateway to Local Adoption Series

Latest content

Rhythm AI’s STAR Apollo system receives FDA clearance for atrial fibrillation

February 12, 2026

iOrganBio appoints Karol Jarzabek as Chief Operating Officer

February 12, 2026

Ensera Design expands UK leadership team with new senior appointments

February 11, 2026

Infinitopes announces $15.4m in additional seed funding to advance cancer vaccine

February 11, 2026

Angelini Pharma appoints Roberto Scrivo as Chief of External Affairs, Communication and Sustainability Officer

February 10, 2026